Astellas Pharma Inc.  _ Annual Report 2014 42 0 150 100 50 64.4 12.2 15.0 36.6 0.7 120.6 54.6 54.6 18.7 44.7 2.5 120.2 18.3 44.7 2.5 2013.3 2014.3 IFRS J-GAAP  Tarceva   Eligard   XTANDI   Gonax (¥ billion) +87% (as of August 1, 2014) Project Phase 1 Phase 2 Phase 3 Filed Enzalutamide (XTANDI) Prostate cancer: pre-chemo, EU/US/JP/Asia (Filed in EU/US) Non-metastatic castration-resistant prostate  cancer: EU/US/Asia Breast cancer: EU/US Erlotinib (Tarceva) Pediatric ependymoma: US Degarelix (Gonax) Prostate cancer: Japan (3-month formulation) ASP1707 Prostate  cancer ASP2215 Acute Myeloid  Leukemia ASP5878 Cancer AMG 337 Gastric  cancer: Japan ASP8273 Non-small cell  lung cancer Rilotumumab  AMG 102 Gastric cancer: Japan AGS-16M8F/  AGS-16C3F Renal cancer ASG-22ME Solid tumors ASG-15ME Bladder  cancer AGS67E Lymphoid  malignancy Antibody Small molecule Oncology Pipeline Total Sales of XTANDI, Tarceva, Eligard and Gonax  XTANDI is a significant growth driver for us in the  oncology field. It grew significantly with the U.S. net sales  of US$441 million in fiscal 2013, an increase of 201% in  year-on-year terms. XTANDI was launched in the U.K. in  July 2013 and later in other EMEA markets. Net sales in  EMEA in fiscal 2013 totaled  € 71 million. In Japan, we  launched XTANDI in May 2014 after gaining regulatory  approval in March. The product is currently available in  over 25 countries around the world. With the aim of maxi- mizing the value of XTANDI, we have filed applications in  Europe and the U.S. for its approval for prostate cancer  in chemotherapy-naïve patients. Clinical trials in earlier  stage prostate cancer and breast cancer patients are  also ongoing. As for new drug candidates, clinical trials are also  ongoing for more than ten projects in the oncology field  at present. Eligard is currently marketed in EMEA, Asia & Oceania.  Net sales in EMEA in fiscal 2013 declined 0.5% to  € 139  million. Sales of Gonax, which was launched in Japan in  October 2012, was ¥2.5 billion in fiscal 2013. In fiscal 2013, Tarceva-related revenues grew steadily,  increasing 1.4% year on year on a U.S. dollar basis to  US$446 million. In the U.S., Astellas is co-promoting  Tarceva with Genentech, Inc., with earnings split equally.  In regions outside the U.S., Astellas has a license agree- ment with F. Hoffmann-La Roche Ltd and receives   royalties based on sales. Our current oncology product lineup consists of  XTANDI, Eligard and Gonax (all prostate cancer treatments)  and Tarceva (for treatment of non-small cell lung cancer  and pancreatic cancer). Aggregate sales of these four  products saw sales in the oncology field soar 87% year  on year in fiscal 2013 to ¥120.6 billion. Astellas is focusing on establishing a Global Category  Leader (GCL) position in the field of oncology after urology  and transplantation. Oncology New drug XTANDI is driving strong growth in our oncology franchise toward GCL status.